Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LA RÉUNION · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a telemonitoring device that helps track the temperature of children at risk of developing a serious condition called febrile neutropenia after chemotherapy. Febrile neutropenia can happen when a patient has a low white blood cell count and develops a fever, which can be dangerous. The study will look at how well families can use this device at home to monitor their child's temperature and whether this method is as effective as having a nurse check their temperature twice a day. Researchers want to know if families are satisfied with the device, if it works properly, and if parents can use it correctly.

To be eligible for this study, children must be between the ages of 0 to 17, be undergoing treatment for cancer, and have recently started chemotherapy. Additionally, their families should face certain challenges that make it harder for them to get support. If a child has skin conditions that prevent the use of the device or chooses not to participate, they won’t be included in the study. The trial is not yet recruiting participants, but it aims to provide valuable insights into how technology can support families during a difficult time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient
• • Aged 0 to 17 inclusive
• • Followed in the Pediatric Onco-Hematology Department
• • Primo-diagnosed with solid or hematological cancer (incident case)
• • Having received a first cycle of chemotherapy
• • Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.
• Exclusion Criteria:
• Patient:
• • with a dermatosis contraindicating the use of the device
• • Refusing to participate in the study